Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tamibarotene - Syros Pharmaceuticals

Drug Profile

Tamibarotene - Syros Pharmaceuticals

Alternative Names: AM-80; Amnoid; Amnolake; INNO-507; NSC-608000; OMS0728; Retinobenzoic acid; RR-110; SY-1425; Tamibaro; Tamibarotene; TM-411; TOS-80T; Z-208

Latest Information Update: 04 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Childrens Hospital Los Angeles; CytRx Corporation; GNI; Nippon Shinyaku; Ohara Pharmaceutical; Syros Pharmaceuticals; TMRC Co. Ltd; Toko Pharmaceutical Industrial; Zeria
  • Class Antineoplastics; Benzoates; Retinoids; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase II Acute myeloid leukaemia
  • No development reported Neutropenia; Solid tumours
  • Discontinued Breast cancer; Crohn's disease; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 12 Nov 2019 Syros Pharmaceuticals intends to complete enrolment in the ongoing phase II trial in Acute myeloid leukaemia (Combination therapy with azacitidine, First-line therapy, Newly diagnosed) in Q4 2019
  • 04 Nov 2019 Updated efficacy and adverse events data from a phase II trial in Acute myeloid leukaemia released by Syros Pharmaceuticals
  • 17 Jan 2019 Discontinued - Phase-II for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in France (PO) (Syros Pharmaceuticals pipeline, January 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top